Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 109-113

  Markman, Maurie ^a,b   Webster, Kenneth ^a   Zanotti, Kristine ^a   Kulp, Barbara ^a   Peterson, Gertrude ^a   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy induced bone marrow suppression; Oral chemotherapy; Ovarian cancer; Platinum resistant ovarian cancer; Topotecan

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; HEMOGLOBIN; PACLITAXEL; PLATINUM; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; UTERINE TUBE DISEASE;

EID: 4644280614     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.017     Document Type: Article

References (27)

1. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
2. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
3. M. Markman Optimizing primary chemotherapy in ovarian cancer Hematol./Oncol. Clin. N. Am. 17 2003 957 968
4. M. Markman, and M.A. Bookman Second-line treatment of ovarian cancer Oncologist 5 2000 26 35
5. G.J. Creemers, G. Bolis, M. Gore, G. Scarfone, A.J. Lacave, and J.P. Guastalla Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J. Clin. Oncol. 14 1996 3056 3061
6. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J. Clin. Oncol. 16 1998 3345 3352
7. W.P. McGuire, J.A. Blessing, M.A. Bookman, S.S. Lentz, and C.J. Dunton Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study J. Clin. Oncol. 18 2000 1062 1067
8. W. ten Bokkel Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, and I. Hudson Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J. Clin. Oncol. 15 1997 2183 2193
9. P.J. Houghton, P.J. Cheshire, L. Myers, C.F. Stewart, T.W. Synold, and J.A. Houghton Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors Cancer Chemother. Pharmacol. 31 1992 229 239
10. J. Verweij, B. Lund, J. Beijnen, A. Planting, M. de Boer-Dennert, and I. Koier Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor Ann. Oncol. 4 1993 673 678
11. D.S. Miller, J.A. Blessing, S.S. Lentz, and D.S. McMeekin Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group study Cancer 98 2003 1664 1669
12. M. Markman, J.A. Blessing, R.D. Alvarez, P. Hanjani, S. Waggoner, and K. Hall Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 77 2000 112 115
13. P. Hoskins, E. Eisenhauer, S. Beare, M. Roy, P. Drouin, and G. Stuart Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study J. Clin. Oncol. 16 1998 2233 2237
14. H. Hochster for the New York Gynecologic Oncology Group Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy J. Clin. Oncol. 17 1999 2553 2561
15. C.J.H. Gerrits, H. Burris, J.H.M. Schellens, A.S.T. Planting, M.E.L. van den Burg, and G.I. Rodriguez Five days of oral topotecan (Hycamtin®), a phase I and pharmacological study in adult patients with solid tumours Eur. J. Cancer 34 1998 1030 1035
16. C.J.H. Gerrits, J.H.M. Schellens, H. Burris, J.R. Eckardt, A.S.T. Planting, and M.E.L. van der Burg A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin. Cancer Res. 5 1999 69 75
17. W.J. Loos, H. Gelderblom, A. Sparreboom, J. Verweij, and M.J.A. de Jonge Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens Clin. Cancer Res. 6 2000 2685 2689
18. D.L. Clarke-Pearson, L. Van Le, T. Iveson, C.W. Whitney, P. Hanjani, and G. Kristensen Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer J. Clin. Oncol. 19 2001 3967 3975
19. M. Gore, A. Oza, G. Rustin, J. Malfetano, H. Calvert, and D. Clarke-Pearson A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer Eur. J. Cancer 38 2002 57 63
20. S.C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, and S. Hearn Phase II study of oral topotecan in advanced non-small cell lung cancer Clin. Cancer Res. 6 2000 868 873
21. J. Von Pawel, U. Gatzemeier, J.-L. Pujol, L. Moreau, S. Bildat, and M. Ranson Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer J. Clin. Oncol. 19 2001 1743 1749
22. G.J. Creemers, C.J. Gerrits, J.R. Eckardt, J.H. Schellens, H.A. Burris, and A.S. Planting Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors J. Clin. Oncol. 15 1997 1087 1093
23. S. Jones, J. Kuhn, E. Raefsky, D. Thompson, F. Greco, and J. Hainsworth A phase I study or oral topotecan in patients with refractory and/or advanced malignancies Proc. Am. Soc. Clin. Oncol. 19 2000 199a (abstract 776)
24. H. Hochster, L. Liebes, J. Speyer, J. Sorich, B. Taubes, and R. Oratz Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen J. Clin. Oncol. 12 1994 553 559
25. G.J. Creemers, C.J.H. Gerrits, J.H.M. Schellens, A.S.T. Planting, M.E.L. van der Burg, and V.M. van Beurden Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer J. Clin. Oncol. 14 1996 2540 2545
26. H. Hochster, L. Liebes, J. Speyer, J. Sorich, B. Taubes, and R. Oratz Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study Clin. Cancer Res. 3 1997 1245 1252
27. J.A. Bridgewater, A.E. Nelstrop, G.J.S. Rustin, M.E. Gore, W.P. McGuire, and W.J. Hoskins Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel J. Clin. Oncol. 17 1999 501 508